Phase 2 of the Global Research on Antimicrobial Resistance (GRAM) Project

The first iteration of the GRAM project represented the single largest assembly of global data on AMR but contained significant gaps geographically and by infectious syndromes in some cases. The first priority is to consolidate the global burden estimation of AMR and integrate it into the global burden of disease enterprise so that it can be produced on a regular basis, and to make the process of integration of the estimation of AMR sustainable and ongoing. Furthermore, better coverage of data through an expanded network of collaborators and targeted acquisition of data to fill key gaps will help produce improved estimates of the public health and clinical burden caused by drug resistant infections and help address the most important data gaps identified in GRAM-1. In order to fully utilise the data, there is a need to maximise the value of the investment and provide increasingly robust estimates on the burden of AMR, at country level over time. Continued analysis with more data will also help us better understand differences in the impact of AMR between countries or over time. This application contributes to shared activities for GRAM-2 and will be jointly funded by DHSC.